Intravenous (IV) Iron Drugs Market Size, Share, Trends, Growth, and Forecasts for 2025 - 2032

The global Intravenous (IV) Iron Drugs Market size is likely to be valued at US$ 3.7 Bn in 2025, andis expected to reach US$ 6.6 Bn by 2032, growing at CAGR of 8.7% during forecast period 2025-2032.

The global intravenous (IV) iron drugs market, growth factor is the increasing prevalence of iron deficiency anemia, particularly among patients with chronic kidney disease (CKD), cancer, and gastrointestinal disorders, which significantly boosts demand for intravenous iron replacement. Rising adoption of best IV iron formulations such as ferric carboxymaltose and iron sucrose in hospitals and clinics enhances market expansion. Increased healthcare spending in emerging markets, along with parenteral nutrition iron additives for critical care patients, is also supporting market growth.

Key Industry Highlights

• Leading Product: Ferric Carboxymaltose holds a 50% market share in 2025, driven by best IV iron formulations for chronic kidney disease.
• Dominant Application: Chronic Kidney Disease accounts for 33% market share, supported by hemodialysis patients iron treatment.
• Fast-growing Application: Cancer is driven by intravenous iron drugs for anemia treatment.
• Dominant Region: North America holds a 50% market share, with the U.S. leading in hospital-based iron infusion drugs.
• Fast-growing Region: Asia Pacific driven by iron infusion drugs and blood disorder medications. Rising rates of CKD, anemia, and cancer, along with increasing investment in healthcare systems and adoption of IV iron replacement therapies.

Driver - Rising Prevalence of Chronic Kidney Disease and Anemia

The intravenous (IV) iron drugs market is propelled by the rising prevalence of chronic kidney disease (CKD) and associated anemia, driving demand for iron therapy, iron injection, and best IV iron formulations for chronic kidney disease. In 2025, CKD affected over 800 Mn people globally, with 15% of U.S. adults impacted, boosting hemodialysis patients iron treatment by 20%. Anemia, a common CKD complication, affects 15.4% of CKD patients in the U.S., necessitating infusion iron replacement and IV iron formulations. Ferric carboxymaltose, with 90% bioavailability, supports drip-based hematinic solutions for rapid correction, reducing red blood cell transfusion needs by 30%. FDA approvals, such as Injectafer for pediatric IDA in 2025, increased hospital-based iron infusion drugs adoption by 15%, Erythropoiesis-stimulating agents (ESAs) complement iron infusion drugs, with 40% of CKD patients using combination therapy, driving blood disorder medications demand across chronic kidney disease applications.

Restraint - Adverse Reactions and Regulatory Challenges

Adverse reactions and stringent regulatory frameworks pose significant restraints to the intravenous iron (IV) drugs market, impacting IV iron drugs and infusion iron replacement. In 2025, 15% of patients reported hypersensitivity reactions to iron infusion drugs, limiting adoption of iron polymaltose and hematinic agents. Regulatory bodies such as the FDA and European Medicines Agency impose strict guidelines, with 25% of new IV iron formulations facing delayed approvals due to safety concerns. These regulations increase development costs for hospital-based iron infusion drugs by 20%, particularly affecting parenteral nutrition iron additives and drip-based hematinic solutions scalability in emerging markets. The need for post-marketing surveillance and risk management plans adds to the operational burden on manufacturers of iron infusion drugs, IV iron formulations, and blood disorder medications, ultimately slowing down innovation and adoption in the IV iron drugs market.

Opportunity - Advancements in Novel IV Iron Formulations

Advancements in novel IV iron formulations, such as nanoparticle-based and liposome-encapsulated iron, present significant opportunities for the intravenous (IV) iron drugs market. In 2025, 20% of new formulations adopted nanotechnology, enhancing bioavailability by 25%, driving demand for ferric carboxymaltose and iron infusion drugs. These reduces side effects, with 10% fewer adverse reactions, supporting best IV iron formulations for chronic kidney disease and blood disorder medications. Emerging markets, with US$ 50 Bn in healthcare investments, offer potential for drip-based iron replacement and parenteral nutrition iron additives, particularly in cancer and inflammatory bowel disease applications. The integration of nanotechnology-based iron formulations, liposomal delivery systems, and next-gen parenteral iron therapy solutions positions the market for sustained growth while reducing the overall burden of anemia-related complications globally.

Product Insights

Ferric Carboxymaltose holds a 50% market share in 2025, driven by best IV iron formulations for chronic kidney disease. it offers superior safety and efficacy for drip-based hematinic solutions. It allows the administration of high single doses, reducing the frequency of iron infusion drugs and improving patient compliance. ferric carboxymaltose is widely adopted for parenteral iron therapy across multiple clinical applications, including blood disorder medications and oncology care, further strengthening its dominance in the IV iron formulations segment.

Iron sucrose is fueled by IV iron replacement demand. It plays a central role in managing anemia among hemodialysis patients, especially those undergoing chronic kidney disease (CKD) treatment, where oral iron therapy proves insufficient. The demand for iron sucrose injection continues to rise because of its cost-effectiveness and reliability in addressing anemia in hemodialysis patients iron treatment.

Application Insights

Chronic kidney disease commands a 33% market share in 2025, driven by hemodialysis patients iron treatment. With 30% of IV iron use in CKD in 2025, it relies on IV iron formulations and erythropoiesis-stimulating agents (ESAs). Patients undergoing hemodialysis often suffer from iron deficiency anemia, making iron deficiency anemia therapy a critical component of their care. Hospital-based IV iron therapy trends and dialysis center demand further drive the segment, as iron infusion drugs are integral for managing anemia in hemodialysis patients.

Cancer is fueled by IV iron drugs for anemia treatment. it supports blood disorder medications for chemotherapy-induced anemia. Iron infusion drugs and infusion iron replacement are essential for restoring hemoglobin levels in these patients, reducing the need for blood transfusions. Advanced IV iron formulations such as ferric derisomaltose and iron polymaltose are being adopted in oncology to ensure safe, effective iron replenishment with minimal side effects.

North America Intravenous (IV) Iron Drugs Market Trends

North America holds a 50% global market share in 2025, with the U.S. leading due to advanced healthcare infrastructure, generating US$ 1.92 Bn in sales. The U.S. market grows at a CAGR of 9.3%, driven by hospital-based iron infusion drugs, with 15% of adults affected by CKD. Best IV iron formulations for chronic kidney disease, such as ferric carboxymaltose and ferric derisomaltose, dominate the market due to their proven safety and efficacy. Key drivers include a 20% increase in cancer cases, boosting IV iron drugs for anemia treatment. American Regent, Inc. holds a 15% regional share, leveraging ferric carboxymaltose for hemodialysis patients iron treatment. The rise of market share of IV iron drugs by region increased IV iron formulations adoption by 25%. Increasing prevalence of inflammatory bowel disease and cancer provides new opportunities for infusion iron replacement and hospital-based iron infusion drugs.

Europe Intravenous (IV) Iron Drugs Market Trends

Europe accounts for a 26% global share, led by Germany, the UK, and France. Cancer patients in Europe frequently require infusion iron drugs for anemia treatment, particularly to manage chemotherapy-induced anemia, boosting demand for injectable iron supplements and infusion hematinic solutions. Germany’s market grows at a CAGR of 8.8%, driven by blood disorder medications, with 55% of hospitals adopting iron infusion drugs. The chronic kidney disease sector, with €1.5 Bn in healthcare spending, drives 15% growth in infusion hematinic solutions.

The UK market is propelled by hemodialysis patients iron treatment, with NHS approving ferric carboxymaltose. France sees 10% growth in inflammatory bowel disease applications, driven by IV iron formulations. Vifor Pharma leads with integrated IV iron solutions. Due to adverse reaction concerns, Europe enforces robust pharmacovigilance programs for iron infusion drugs, particularly affecting iron polymaltose and similar hematinic agents. The adoption of next-generation IV iron formulations, including nanoparticle-based iron drugs, is accelerating, improving safety and reducing hypersensitivity risks.

Asia Pacific Intravenous (IV) Iron Drugs Market Trends

Asia Pacific is the fastest-growing region, with a CAGR of 9.5%, led by China, Japan, and India. China holds a 40% regional share, fueled by US$ 200 Bn in healthcare investments, boosting iron infusion drugs and parenteral nutrition iron additives. India’s market propelled by 25% growth in IDA cases, with 35% adoption of infusion iron replacement. Increasing use of IV iron drugs for anemia treatment in cancer patients undergoing chemotherapy in urban hospitals. Japan’s market witnessed 12% growth in hospital-based iron infusion drugs, driven by aging population.

Pharmacosmos A/S expands with ferric carboxymaltose, capturing 10% of the regional market. Rising healthcare expenditure in India and China creates a favorable environment for the adoption of IV iron formulations in blood disorder medications and hospital-based IV iron therapy. Partnerships between global manufacturers and local distributors are improving accessibility to injectable iron supplements and ferric carboxymaltose.

The global Intravenous (IV) iron drugs market is highly competitive, with Sanofi, Pharmacosmos A/S, AbbVie, Daiichi Sankyo, Novartis, Hoffmann-La Roche, Pfizer, Vifor Pharma, Luitpold Pharmaceuticals, LLC, Fresenius Kabi AG, Baxter International Inc., and American Regent, Inc. focusing on iron therapy, iron injection, and IV iron drugs. Companies leverage ferric carboxymaltose, hematinic agents, and erythropoiesis-stimulating agents (ESAs) to gain market share. Strategic R&D investments in best IV iron formulations for chronic kidney disease and partnerships drive intravenous iron replacement, addressing blood disorder medications and hemodialysis patients iron treatment needs.

Industry Developments:

• In 2024, Pharmacosmos A/S launched its ferric derisomaltose (FDI) formulation, known as Monofer, around 2010 as a high-dose, controlled-release intravenous iron therapy for iron deficiency anemia. This non-dextran formulation offers flexible dosing and a high dose (up to 2000 mg) in a single infusion, with a favorable safety profile that minimizes toxicities and hypersensitivity reactions, even reducing the risk of hypophosphatemia compared to older ferric carboxymaltose (FCM) formulations.
• In 2023, The FDA has approved ferric carboxymaltose injection (Injectafer; Daiichi Sankyo Inc. and American Regent Inc.) for the treatment of iron deficiency in adult patients with heart failure categorized as New York Heart Association (NYHA) class 2/3 to improve exercise capacity.